Maze Therapeutics Inc
MAZE8.210
+0.510+6.62%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
--Marktkapitalisierung
--KGV TTM
mehr Informationen über Maze Therapeutics Inc Unternehmen
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Unternehmensinformationen
Unternehmens-codeMAZE
Name des UnternehmensMaze Therapeutics Inc
IPO-datumJan 31, 2025
Gegründet am2017
CEODr. Jason V. Coloma, Ph.D.
Anzahl der mitarbeiter125
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse171 Oyster Point Boulevard, Suite 300
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16508505070
Websitehttps://www.mazetx.com/
Unternehmens-codeMAZE
IPO-datumJan 31, 2025
Gegründet am2017
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ms. Jillian Connell
Ms. Jillian Connell
Investor Relations
Investor Relations
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Independent Director
Independent Director
20.74K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Mr. Neil Exter
Mr. Neil Exter
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sun, Apr 27
Update-Zeit: Sun, Apr 27
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Aktionärsstatistik
Aktionäre
Anteil
Third Rock Ventures, LLC
16.04%
ARCH Venture Partners
9.41%
Frazier Life Sciences Management, L.P.
7.29%
Deep Track Capital LP
6.90%
Matrix Capital Management Company, LP
5.68%
Other
54.68%
Art
Aktionäre
Anteil
Venture Capital
27.81%
Private Equity
12.90%
Investment Advisor/Hedge Fund
8.50%
Hedge Fund
6.90%
Individual Investor
5.91%
Corporation
5.51%
Investment Advisor
2.60%
Family Office
1.10%
Other
28.77%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
16
30.56M
69.78%
+23.42M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Third Rock Ventures, LLC
12.79M
29.2%
+5.76M
+82.04%
Feb 03, 2025
ARCH Venture Partners
4.12M
9.41%
+4.12M
--
Jan 31, 2025
Deep Track Capital LP
3.02M
6.9%
+3.02M
--
Jan 31, 2025
Matrix Capital Management Company, LP
2.49M
5.68%
+2.49M
--
Jan 31, 2025
Foresite Capital Management, LLC
2.46M
5.61%
+2.46M
--
Jan 31, 2025
Alphabet Holdings L.L.C.
2.41M
5.51%
+2.41M
--
Jan 31, 2025
Brush (James)
1.63M
3.73%
+1.63M
--
Jan 31, 2025
The Vanguard Group, Inc.
49.15K
0.11%
+348.00
+0.71%
Feb 28, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten